Eli Lilly: Sticking With A $1000 Target Ahead Of Q3 Earnings, New ...
WEB4 hours ago · Eli Lilly surged 58% in 2024, driven by weight-loss drugs and strong earnings. ... Of course, any negative news regarding GLP-1 side effects or adverse FDA decisions could weigh on this high-P/E ...
Eli Lilly: I Admit Defeat As I Understated Its Growth Prospects ...
WEB21 hours ago · Eli Lilly and Company (NYSE: LLY) investors have continued to lift its momentum as the leading GLP-1 weight loss drugs maker lifted its guidance at its recent earnings scorecard in August 2024. As ...
Lilly expands manufacturing footprint in Ireland with $1.8 billion ...
WEBINDIANAPOLIS, Sept. 12, 2024 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) today announced a $1 billion expansion of its Limerick, Ireland, manufacturing site to increase production of biologic active ingredients, including those for its recently approved treatment for early symptomatic Alzheimer's disease.
Lilly.com | Eli Lilly and Company
WEBINDIANAPOLIS , Sept. 9, 2024 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) today announced the appointment of Lucas Montarce as executive vice president and chief financial officer (CFO) and member of the company's …
Eli Lilly and Company (LLY) Latest Stock News & Headlines
WEBGet the latest Eli Lilly and Company (LLY) stock news and headlines to help you in your trading and investing decisions.
Eli Lilly (LLY) earnings Q2 2024 - CNBC
WEBAug 8, 2024 · That compares with a profit of $1.76 billion, or $1.95 a share, a year earlier. Excluding one-time items associated with the value of intangible assets and other adjustments, Eli Lilly posted ...
All News - Eli Lilly and Company
WEBLilly's latest press releases, stories, news resources and more.
News Release - Eli Lilly and Company
WEBINDIANAPOLIS, April 17, 2024 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) today announced positive topline results of the SURMOUNT-OSA phase 3 clinical trials that showed tirzepatide injection (10 mg or 15 mg) significantly reduced the apnea-hypopnea index (AHI) compared to placebo, achieving the primary endpoints.
Next-generation drug from Eli Lilly boosts weight loss to 24% ... - CNN
WEBJun 26, 2023 · Eli Lilly’s Mounjaro, cleared for type 2 diabetes and awaiting FDA approval for weight loss, targets both GLP-1 and a hormone called GIP, and has produced weight loss of 21 to 23%.
News Release - Eli Lilly and Company
WEBFDA approves Lilly's Mounjaro™ (tirzepatide) injection, the first and only GIP and GLP-1 receptor agonist for the treatment of adults with type 2 diabetes. May 13, 2022. PDF Version. Mounjaro delivered superior A1C reductions versus all comparators in phase 3 SURPASS clinical trials.
- Some results have been removed
Skip to content